UAE Obesity Statistics 2026: Burden, Policy Response & the GLP-1 Market Landscape

What Is the Most Useful Way to Measure Obesity in the UAE?

The most defensible answer is that there is no single UAE obesity number; there are different numbers for different jobs. WHO’s age-standardized national estimate is the right reference if the goal is cross-country comparison. The Dubai Academic Health Corporation paper is more useful if the goal is to understand the burden showing up in a large real-world urban health-system sample. The two should not be treated as contradictory. They measure different populations and different summary frames.

The Dubai study is especially important because it is the largest obesity prevalence dataset yet published from the region, covering 440,590 adults attending public-sector sites between 2018 and 2023. It found that 63.4% were living with overweight or obesity and 28.0% with obesity. UAE nationals had a heavier burden than other population groups in the dataset, reaching 68.3% living with overweight or obesity. For searchers asking why UAE obesity figures look different across websites, this is usually the answer: some pages cite a national obesity-only estimate, while others cite a Dubai overweight-plus-obesity sample.

Here, the job is not to tell readers what a prescription product costs. It is to explain why the UAE has become such an important metabolic-disease market in the first place, which starts with reading the burden data correctly.

How Large Is the Linked Diabetes and Obesity Burden?

The obesity conversation becomes much more consequential once it is paired with the UAE diabetes profile. The IDF Diabetes Atlas 11th edition estimates that 1.274 million adults in the UAE were living with diabetes in 2024, and that the age-standardized prevalence was 20.7%. That is why the UAE repeatedly appears in global metabolic-disease discussions even when country-level obesity estimates vary by method.

One of the most important details in the IDF profile is not prevalence alone but detection. The Atlas estimates that 64.0% of diabetes cases in the UAE are undiagnosed. That matters for market interpretation: a large metabolic burden does not automatically mean neat, fully identified treatment pathways. It means health systems, screening programs, primary care, and pharmacy demand can all move at different speeds.

For GLP-1 research, that combination of high excess-weight burden, high diabetes prevalence, and large undiagnosed share is the real story. It creates a market where demand is not being driven by one variable such as aesthetics or trend usage alone. The category sits on top of a broader metabolic screening and chronic-disease problem.

What Is the Official United Arab Emirates Policy Response?

The official stance has become clearer in the last year. In March 2025, MoHAP described obesity as a strategic priority for the UAE health system. Its burden extends well beyond diabetes to cardiovascular disease and other chronic conditions: higher-than-optimal body weight is linked to an estimated 3.7 million deaths a year worldwide and is a major risk factor for several cancers. In the same update, the ministry pointed to collaboration with WHO, school-health and childhood-obesity initiatives, training on obesity indicators, and work on a national scientific guide for obesity management and weight control, in line with broader clinical practice recommendations.

MoHAP also said the then-upcoming National Health and Nutrition Survey would measure obesity rates among adults and children across the country, including body mass index, waist circumference, and clearer obesity-diagnosis thresholds. That survey (2024–2025) has since been published and reports 22.4% of adults living with obesity. That matters because it signals a move from broad awareness messaging toward more standardized national measurement. For researchers and analysts, that is one of the strongest clues that obesity in the UAE is now being treated as an infrastructure question, not just a lifestyle topic — a direction reinforced by the role of the Dubai Health Authority and routine sampling in public health facilities as the system builds more consistent national data.

World Obesity Federation arrives at the same issue from a different angle. Its 2024 UAE briefing warns that the economic impact of obesity is on track to approach 5% of GDP by 2035. That estimated total folds in indirect costs such as lost productivity alongside direct healthcare spending, and it reflects rising pressure for prevention and treatment pathways, including earlier lifestyle intervention. The figure is not a prevalence number, but it is a useful reminder that the UAE obesity story is already an economic and system-capacity story, not only an individual-risk story.

How Should Readers Interpret the UAE GLP-1 and Lifestyle Intervention Landscape?

The right interpretation is that UAE GLP-1 demand is being built by epidemiology first and product competition second. Obesity and diabetes prevalence create the underlying demand pool; policy attention, screening efforts, and clinician adoption determine how fast that demand becomes visible in prescribing and pharmacy channels. This is why the UAE matters in the broader incretin conversation even when brand-level pricing or availability changes month to month. Alongside the new National Health and Nutrition Survey 2024–2025 (adult obesity 22.4%), the earlier UAE National Health Survey 2017–2018 remains a useful benchmark, reporting adult obesity at 27.8%. In practice, an obesity diagnosis is often standardized with more than body mass index alone, with waist circumference also used to gauge cardiometabolic risk.

That is also why we keep this page separate from our brand-by-brand UAE GLP-1 availability and cost guide. If you need prescription access rules, approximate pharmacy pricing, or brand comparisons, use that page. If you need the why now behind the UAE metabolic market, this is the better starting point. It is also why screening and treatment capacity belong in the picture: obesity care spans lifestyle intervention and structured medical management through to bariatric surgery in severe cases, and how much of that pathway a health system can deliver shapes how underlying burden converts into measured demand.

2026 Landscape Updates

UAE Approval of Foundayo — Early April 2026 (Second Country Worldwide)

Foundayo (orforglipron) was approved in the UAE in early April 2026, making the UAE the second country in the world to approve the first oral non-peptide GLP-1 receptor agonist for chronic weight management. First supplies became available in May 2026. The FDA had approved Foundayo on April 1, 2026. Unlike Rybelsus or other oral peptide formulations, it has no food or water restrictions. For mechanism, dosing, and trial data, see the Foundayo orforglipron profile. Sources: gulfnews.com; khaleejtimes.com.

Novo Nordisk: UAE Global Pharmaceutical Distribution Hub (May 22, 2026)

Novo Nordisk and UAE health authorities announced on May 22, 2026 that the UAE would serve as one of three global pharmaceutical distribution hubs worldwide, supporting approximately 70 countries and 2.6 million patients. This is a supply-chain and trust signal: distribution infrastructure for incretin medicines is being built in partnership with the UAE federal regulator. Sources: gulfnews.com; healthcaremea.com; khaleejtimes.com.

Retatrutide TRIUMPH-1 Readout — May 21, 2026

Retatrutide’s pivotal TRIUMPH-1 obesity readout was reported on May 21, 2026 and is relevant input for landscape forecasting in this region. Retatrutide remains investigational and is not an approved UAE medicine; nothing here suggests otherwise. The reason it earns a place in a UAE obesity-landscape page is forward-looking: triple-agonist Phase 3 data anchors where the obesity pharmacology ceiling is heading, and that ceiling moves how analysts size the regional category over the next several years. UAE regulatory pathways for retatrutide are not yet announced and we do not speculate on them. See the Dubai research guide for full research-use context.

Retatrutide TRIUMPH-2 and TRIUMPH-3 — July 23, 2026; FDA Filing Planned Q1 2027

Lilly reported two more positive Phase 3 toplines on July 23, 2026. In TRIUMPH-2 (adults with obesity and type 2 diabetes, 80 weeks), mean weight loss was 12.7%, 19.1% and 20.8% at 4, 9 and 12 mg versus 4.0% on placebo, with A1C reductions of up to 1.6 points. In TRIUMPH-3 (severe obesity with established cardiovascular disease, 80 weeks), weight loss was 21.6% and 22.6% at 9 and 12 mg versus 3.2% on placebo. Lilly plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027. Retatrutide is not approved anywhere, including the UAE. Approval timing across the category is tracked in the retatrutide approval tracker.

Wegovy Pill — Available in the UAE

When the European Commission approved the Wegovy pill on July 15, 2026, Novo Nordisk said the pill was already available in the United States, the UK and the UAE, with more launches planned for the second half of 2026. Source: reuters.com.

Incretin Market Scale — Lilly Q2 & Novo Q1 2026

Global incretin demand helps frame UAE projections. Lilly Q2 2026 (August 5, 2026): Mounjaro WW revenue $9.9B (+91% YoY); Zepbound $4.9B (+44%); total Lilly $23.0B (+48%); Foundayo $98M in its first reported quarter. Novo Nordisk Q1 2026 (May 6, 2026): total DKK 96.8B (+32% CER); obesity care +22% CER; Wegovy pill first launch quarter DKK 2.26B. Cited as global market-size context. Sources: prnewswire.com; novonordisk.com.

UAE 2031 Obesity Macro Report — Government Priority Signal

A May 2026 report by the UAE Ministry of Economy, Whiteshield, and Eli Lilly modeled accelerated intervention outcomes: 1.2M+ adults could exit obesity by 2031, delivering a ~15-percentage-point prevalence decline, +$51B in GDP, and $1.5B in healthcare savings. This is a forward-looking economic model, co-authored by the UAE government, signaling that obesity has moved firmly into the national economic-development agenda. Sources: aletihad.ae; healthcaremea.com; emirates247.com.

Where Does Retatrutide Fit in This Landscape?

Retatrutide belongs in the research and pipeline layer, not the approved-prescription layer. It is a next-generation triple-agonist candidate often discussed alongside semaglutide, tirzepatide, and CagriSema when analysts map where obesity pharmacology may be heading. On this site, it is covered strictly in research-use terms and should not be presented as an approved UAE treatment product. For research-use context, Remy Research documents each retatrutide pen and vial format in its UAE catalogue with batch-matched Janoshik COAs.

If you want a deeper research-only breakdown, use our Dubai research guide. If you want a mechanism and pipeline comparison, use our retatrutide vs tirzepatide vs CagriSema analysis. For approval timing across the wider category, use the obesity drug approval tracker.